CareDx misses Q4 adjusted EPS estimates

CareDx

24/02/2026 21:16

Overview

Transplant solutions firm's Q4 revenue rose 25% yr/yr

Adjusted EPS for Q4 missed analyst expectations

Company repurchased $12 mln worth of shares during Q4

Outlook

CareDx expects full-year 2026 revenue between $420 mln and $444 mln

Company anticipates 2026 adjusted EBITDA between $30 mln and $45 mln

CareDx estimates $7.5 mln impact from Medicare LCD in 2026

Result Drivers

TESTING SERVICES GROWTH - Testing services revenue increased 23% year-over-year, driven by a 17% rise in testing volume

PATIENT AND DIGITAL SOLUTIONS - Revenue from patient and digital solutions grew 47% year-over-year, reflecting strong demand

Company press release: ID:nBw12HmWda

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Miss
$0.12
$0.24 (7 Analysts)
Q4 EPS
-$0.08
Q4 Adjusted Net Income
Miss
$6 mln
$12.27 mln (6 Analysts)
Q4 Net Income
-$4 mln
Q4 Adjusted EBITDA
Miss
$7 mln
$12.60 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CareDx Inc is $25.50, about 35.7% above its February 23 closing price of $18.79

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)